Companies: 10,795·Total market cap: $144.5T
Silexion Therapeutics Ltd.

Silexion Therapeutics Ltd.

SLXNWNASDAQHealthcare● Active
$0.03
$-0.00(-7.82%)
Market Cap$18512
P/E Ratio—
52W High$0.0502
52W Low$0.0311
SEC Filings
Foreign Private Issuer · Files 20-F / 6-K

Silexion Therapeutics Ltd. (SLXNW) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0002022416 · SLXNW · NASDAQ · as of Jun 8, 2026

Filing snapshot

233
Total Filings
PRE 14A
Latest Form
2026-06-03
Most Recent
2024
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0002022416 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-05-19
Fiscal Year End
May 19, 2026
Accession No.
0001178913-26-002805
Primary Document
zk2635370.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0002022416 · Accession 0001178913-26-002805

Latest Key Filings

6-KQuarterly Report

No recent filings

8-KCurrent Report
8-K
2026-05-29Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
PRE 14APRE 14A
PRE 14A
2026-06-03
View
SCHEDULE 13D/ASCHEDULE 13D/A
SCHEDULE 13D/A
2026-05-29
View
8-KCurrent Report
8-K
2026-05-29
View
S-8Employee Stock Plan Registration
S-8
2026-05-28
View
8-KCurrent Report
8-K
2026-05-26
View
10-K/AAnnual Report (Amended)
10-K/A
2026-05-19
View
8-KCurrent Report
8-K
2026-05-18
View
10-QQuarterly Report
10-Q
2026-05-15
View
8-KCurrent Report
8-K
2026-05-15
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
8-KCurrent Report
8-K
2026-05-14
View
8-KCurrent Report
8-K
2026-05-13
View
EFFECTEFFECT
EFFECT
2026-05-11
View
EFFECTEFFECT
EFFECT
2026-05-11
View
POS AMPOS AM
POS AM
2026-05-07
View
Showing 1–15 of 218 filingsForm 4 / 144 hidden· 233 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0002022416  |  Exchange: NASDAQ · Healthcare

Silexion Therapeutics Ltd. (NASDAQ: SLXNW) has submitted 233 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2024. As a Healthcare sector company with CIK 0002022416, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Silexion Therapeutics Ltd.'s most comprehensive regulatory disclosure. The most recent Silexion Therapeutics Ltd. 10-K was filed on 2026-05-19 for fiscal year ending 2026. Historical SLXNW 10-K annual reports are available from 2024 through 2026.

Investors researching Silexion Therapeutics Ltd. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Healthcare
PIII SEC Filings →AKTX SEC Filings →REVB SEC Filings →ACON SEC Filings →DRMA SEC Filings →PPBT SEC Filings →VINC SEC Filings →SYRS SEC Filings →
→ SLXNW Financials→ SLXNW Earnings→ SLXNW Insider Trades

Frequently Asked Questions

SLXNW SEC Filings · 8 questions

Silexion Therapeutics Ltd. (SLXNW) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 233 filings and access original documents at no cost. Silexion Therapeutics Ltd.'s CIK is 0002022416.

SLXNW SEC filingsSilexion Therapeutics Ltd. SEC documentsfind SLXNW 10-K